title: 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.
abstract: The 8th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The new agenda format for 2012 included three parallel tracks on: (1) naked antibodies; (2) antibody drug conjugates (ADCs); and (3) bispecific antibodies and alternative scaffolds. The meeting started and closed with three plenary lectures to give common background and to share the final panel discussion and conclusions. The two day event included case studies and networking for nearly 250 delegates who learned of the latest advances and trends in the global development of antibody-based therapeutics. The monoclonal antibody track was focused on understanding the structure-function relationships, optimization of antibody design and developability, and processes that allow better therapeutic candidates to move through the clinic. Discussions on novel target identification and validation were also included. The ADC track was dedicated to evaluation of the ongoing success of the established ADC formats alongside the rise of the next generation drug-conjugates. The bispecific and alternative scaffold track was focused on taking stock of the multitude of bispecific formats being investigated and gaining insight into recent innovations and advancements. Mechanistic understanding, progression into the clinic and the exploration of multispecifics, redirected T cell killing and alternative scaffolds were extensively discussed. In total, nearly 50 speakers provided updates of programs related to antibody research and development on-going in the academic, government and commercial sectors.
authors.affiliation: Centre d'Immunologie Pierre Fabre; Saint-Julien en Genevois, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.affiliation: Genentech Inc.; South San Francisco, CA USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Carter
authors.affiliation: Pfizer Inc.; New York, NY USA.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Gerber
authors.affiliation: Merimack; Pharmaceuticals, MA USA.
authors.forename: Alexey A
authors.initials: AA
authors.lastname: Lugovskoy
authors.affiliation: Institut de Recherches SERVIER; Croissy-sur-Seine, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.affiliation: Genentech Inc.; South San Francisco, CA USA.
authors.forename: Jagath R
authors.initials: JR
authors.lastname: Junutula
authors.affiliation: Institute of Cell Biology and Immunology; University of Stuttgart; Stuttgart, Germany.
authors.forename: Roland E
authors.initials: RE
authors.lastname: Kontermann
authors.affiliation: Adimab LLC; Lebanon, NH USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Mabry
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D000922:Immunotoxins / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D011485:Protein Binding; D015202:Protein Engineering; D011993:Recombinant Fusion Proteins / Q000276:immunology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins
keywords: antibody-drug conjugates; biosimilar antibodies; bispecific antibodies; protein scaffolds; therapeutic antibodies